false000176230300017623032024-06-052024-06-05

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 05, 2024

 

 

AVITA Medical, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39059

85-1021707

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

28159 Avenue Stanford

Suite 220

 

Valencia, California

 

91355

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 661 367-9170

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

RCEL

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

AVITA Medical, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (“Annual Meeting”) virtually on June 5, 2024 (being June 6, 2024 in Australia).

 

Director and Officer Equity Awards

 

At the Annual Meeting, the Company’s stockholders approved grants of options and restricted stock units to the Company’s non-executive directors and a grant of options to the Company’s Chief Executive Officer. The grants are summarized in Item 5.07 below and in Proposals 3 through 8 (with respect to the non-executive directors) and Proposal 9 (with respect to the Chief Executive Officer) in the Company’s Proxy Statement for the Annual Meeting as filed with the Securities and Exchange Commission on April 23, 2024 (the "Proxy Statement”). The terms and conditions of such grants of options and restricted stock units are described in the Proxy Statement, which disclosure is incorporated by reference into this Item 5.02.

Item 5.07 Submission of Matters to a Vote of Security Holders.

At the Annual Meeting, the Company’s stockholders voted on the proposals summarized in the Proxy Statement as set forth below:

 

1.
Election of Directors (Proposal 1). All seven directors named in the Proxy Statement were elected to serve on the Company’s Board of Directors with the following vote:

 

Name

Votes For

 

Votes Withheld

 

Broker Non-Votes

 

Mr. Louis Panaccio

 

9,639,179

 

 

3,437,336

 

 

2,141,804

 

Mr. James Corbett

 

12,007,045

 

 

1,243,405

 

 

2,141,804

 

Mr. Jeremy Curnock Cook

 

12,084,039

 

 

1,165,850

 

 

2,141,804

 

Professor Suzanne Crowe

 

12,341,978

 

 

908,472

 

 

2,141,804

 

Ms. Jan Stern Reed

 

11,611,092

 

 

1,635,332

 

 

2,141,804

 

Mr. Robert McNamara

 

12,261,891

 

 

988,559

 

 

2,141,804

 

Mr. Cary Vance

 

12,261,730

 

 

988,720

 

 

2,141,804

 

 

2.
Appointment of Independent Auditor (Proposal 2). The stockholders ratified the selection of Grant Thornton LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2024. The votes regarding this proposal were as follows:

 

Votes For

 

Votes Against

 

Abstentions

 

Broker Non-Votes

 

 

14,794,234

 

 

206,185

 

 

366,332

 

 

-

 

 

3.
Issuance of Securities to Non-Executive Directors (Proposals 3 - 8): Stockholders approved the grant of restricted stock units equal in value to $87,500 (at the time of the grant) and the grant of stock options equal in value to $37,500 (at the time of the grant) to each of the six non-executive directors on the terms and conditions set out in the Proxy Statement. The votes regarding these proposals were as follows:

 

 

Votes For

 

Votes Against

 

Abstentions

 

Broker Non-Votes

 

 Mr. Louis Panaccio

 

10,834,366

 

 

1,947,210

 

 

446,306

 

 

2,138,869

 

 Professor Suzanne Crowe

 

10,848,440

 

 

1,915,747

 

 

463,695

 

 

2,138,869

 

 Mr. Jeremy Curnock Cook

 

10,834,337

 

 

1,948,061

 

 

445,484

 

 

2,138,869

 

 Ms. Jan Stern Reed

 

10,696,549

 

 

2,082,094

 

 

449,239

 

 

2,138,869

 

 Mr. Robert McNamara

 

10,837,227

 

 

1,935,886

 

 

454,769

 

 

2,138,869

 

 Mr. Cary Vance

 

10,843,117

 

 

1,935,084

 

 

449,681

 

 

2,138,869

 

 

4.
Issuance of Securities to Mr. James Corbett (Proposal 9): Stockholders approved the grant of options to acquire 350,000 shares of common stock of the Company to the Company’s Chief Executive Officer, Mr. James Corbett, on the terms and conditions set forth in the Proxy Statement. The votes regarding this proposal were as follows:

 

Votes For

 

Votes Against

 

Abstentions

 

Broker Non-Votes

 

 

10,040,922

 

 

2,759,325

 

 

427,635

 

 

2,138,869

 
5.
Advisory Vote to Approve Compensation of Named Executive Officers (Proposal 10): Stockholders voted in favor of the non-binding advisory vote to approve the compensation of the Company’s named executive officers. The votes regarding this proposal were as follows:

 

Votes For

 

Votes Against

 

Abstentions

 

Broker Non-Votes

 

 

10,269,125

 

 

2,296,661

 

 

662,096

 

 

2,138,869

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

AVITA Medical, Inc.

 

 

 

 

Date:

June 6, 2024

By:

/s/ Donna Shiroma

 

 

 

Donna Shiroma
General Counsel

 

v3.24.1.1.u2
Document And Entity Information
Jun. 05, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 05, 2024
Entity Registrant Name AVITA Medical, Inc.
Entity Central Index Key 0001762303
Entity Emerging Growth Company true
Entity File Number 001-39059
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 85-1021707
Entity Address, Address Line One 28159 Avenue Stanford
Entity Address, Address Line Two Suite 220
Entity Address, City or Town Valencia
Entity Address, State or Province CA
Entity Address, Postal Zip Code 91355
City Area Code 661
Local Phone Number 367-9170
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol RCEL
Security Exchange Name NASDAQ
Avita Medical (NASDAQ:RCEL)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas Avita Medical.
Avita Medical (NASDAQ:RCEL)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas Avita Medical.